S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
S&P 500   3,852.36
DOW   32,920.46
QQQ   294.62
7 Safe Investments with Relatively High Returns for 2023
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Lucid Group's Buyout Rumors Continue
These AI, Cloud Stocks are Down Significantly, Not For Long
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Dividend King Sysco: Buying On The Dip 
Will Caterpillar Dig Its Way To Another Buying Opportunity? 
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Wall Street climbs to add more to its strong January
Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
OTCMKTS:NVZMF

Novozymes A/S - NVZMF Stock Forecast, Price & News

$50.86
0.00 (0.00%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$50.86
▼
$50.86
50-Day Range
$48.37
▼
$60.92
52-Week Range
$38.16
▼
$70.50
Volume
200 shs
Average Volume
5,580 shs
Market Capitalization
N/A
P/E Ratio
6.34
Dividend Yield
0.72%
Price Target
N/A

Novozymes A/S MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.61mentions of Novozymes A/S in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.89 out of 5 stars

See Top Rated MarketRank™ Stocks Here

NVZMF stock logo

About Novozymes A/S (OTCMKTS:NVZMF) Stock

Novozymes A/S engages in the research and development of biotechnology solutions, which produces industrial enzymes and microorganisms. Its business areas include agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile and wastewater solutions. The company was founded in 2000 and is headquartered in Copenhagen, Denmark.

Receive NVZMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMF Stock News Headlines

January 25, 2023 | edition.cnn.com
EU red tape creates ‘roadblocks’ on sustainability, says Novozymes boss
January 12, 2023 | finance.yahoo.com
Novozymes A/S (NVZMF)
February 1, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
December 12, 2022 | msn.com
Novozymes is set to merge with Chr. Hansen as part of a historic deal
November 5, 2022 | seekingalpha.com
Novozymes A/S (NVZMF) Q3 2022 Earnings Call Transcript
November 3, 2022 | finance.yahoo.com
Novozymes confirms upgraded guidance by strong start to Q4
November 1, 2022 | finance.yahoo.com
Novozymes Named EPA Safer Choice Partner of the Year for Second Consecutive Year
August 14, 2022 | seekingalpha.com
Novozymes A/S 2022 Q1 - Results - Earnings Call Presentation
February 1, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
August 11, 2022 | finance.yahoo.com
Novozymes delivers strong half year results and narrows full-year outlook upwards
July 15, 2022 | finance.yahoo.com
Novozymes plan to further increase prices across the portfolio in response to the significant and persistent hike in incoming cost
June 7, 2022 | finance.yahoo.com
Novozymes extends the lifetime of textiles with sustainable innovation
April 27, 2022 | seekingalpha.com
Novozymes A/S (NVZMF) CEO Ester Baiget on Q1 2022 Results - Earnings Call Transcript
April 26, 2022 | finance.yahoo.com
Novozymes delivers strong 2022 Q1 results and raises full-year financial guidance
January 18, 2022 | nasdaq.com
Novozymes AS - Class B (NVZMF)
December 16, 2021 | finance.yahoo.com
Closing the gap between sustainability and profits in corn wet milling
December 16, 2021 | finance.yahoo.com
Marrone Bio Optimizes Bioherbicide with New Bacteria Strains, Accelerates Product Development to Enter $27 Billion Herbicide Market¹
December 13, 2021 | finance.yahoo.com
Novozymes and Saipem enter collaboration agreement to create a more sustainable CO2 capture
September 26, 2021 | markets.businessinsider.com
Novozymes A/S : Novozymes is combining cutting-edge science and business expertise to help feed the world sustainably
August 31, 2021 | finanznachrichten.de
Novozymes Bioenergy Business Threatened by Electric Cars, Bank of America Says
August 12, 2021 | finance.yahoo.com
Novozymes reaches a strategic milestone in the implementation of its strategy with a significant entry into Advanced Protein Solutions
August 12, 2021 | finance.yahoo.com
Interim report for 1H 2021
August 12, 2021 | finance.yahoo.com
Novozymes delivers strong Q2 results and narrows full-year guidance to the high-end of the range
May 17, 2021 | finance.yahoo.com
AXTA vs. NVZMY: Which Stock Should Value Investors Buy Now?
April 29, 2021 | finance.yahoo.com
CE vs. NVZMY: Which Stock Should Value Investors Buy Now?
April 29, 2021 | finance.yahoo.com
Professional cleaning companies collaborate to evaluate the benefit of probiotics in green cleaning, in response to COVID-19
April 29, 2021 | seekingalpha.com
Novozymes A/S 2021 Q1 - Results - Earnings Call Presentation
See More Headlines
Receive NVZMF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novozymes A/S and its competitors with MarketBeat's FREE daily newsletter.

NVZMF Company Calendar

Last Earnings
4/20/2016
Today
1/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:NVZMF
CUSIP
N/A
CIK
1131345
Web
www.novozymes.com
Phone
(454) 446-0000
Fax
N/A
Employees
6,184
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
6.34
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Ester Baiget
    President & Chief Executive Officer
  • Graziela Chaluppe dos Santos Malucelli
    Chief Operating Officer & Executive VP
  • Lars Green
    Chief Financial Officer & Executive Vice President
  • Claus Crone Fuglsang
    Executive Vice President-Research & Development
  • Anders Lund
    EVP & Head-Consumer Biosolutions

Key Competitors

View All Competitors













NVZMF Stock - Frequently Asked Questions

How have NVZMF shares performed in 2023?

Novozymes A/S's stock was trading at $50.36 on January 1st, 2023. Since then, NVZMF stock has increased by 1.0% and is now trading at $50.8550.
View the best growth stocks for 2023 here.

Are investors shorting Novozymes A/S?

Novozymes A/S saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 2,732,700 shares, an increase of 41.2% from the December 31st total of 1,935,100 shares. Based on an average daily volume of 3,900 shares, the days-to-cover ratio is presently 700.7 days.
View Novozymes A/S's Short Interest.

How were Novozymes A/S's earnings last quarter?

Novozymes A/S (OTCMKTS:NVZMF) posted its quarterly earnings data on Wednesday, April, 20th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $2.43 by $2.06.

Is Novozymes A/S a good dividend stock?

Novozymes A/S (OTCMKTS:NVZMF) pays an annual dividend of $1.80 per share and currently has a dividend yield of 0.72%. The dividend payout ratio is 22.44%. This payout ratio is at a healthy, sustainable level, below 75%.

What is Novozymes A/S's stock symbol?

Novozymes A/S trades on the OTCMKTS under the ticker symbol "NVZMF."

How do I buy shares of Novozymes A/S?

Shares of NVZMF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novozymes A/S's stock price today?

One share of NVZMF stock can currently be purchased for approximately $50.86.

How many employees does Novozymes A/S have?

The company employs 6,184 workers across the globe.

How can I contact Novozymes A/S?

Novozymes A/S's mailing address is Krogshoejvej 36, BAGSVAERD, 2880, Denmark. The official website for the company is www.novozymes.com. The biotechnology company can be reached via phone at (454) 446-0000.

This page (OTCMKTS:NVZMF) was last updated on 2/1/2023 by MarketBeat.com Staff